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Membrane potentialIn Parkinson's disease (PD), aside from the central lesion, involvement of visceral organs has been proposed
as part of the complex clinical picture of the disease. The issue is still poorly understood and relatively unex-
plored. In this study we used a classic rodent model of nigrostriatal degeneration, induced by the intrastriatal
injection of 6-hydroxydopamine (6-OHDA), to investigate whether and how a PD-like central dopaminergic
denervation may inﬂuence hepatic functions. Rats received an intrastriatal injection of 6-OHDA or saline
(sham), and blood, cerebrospinal ﬂuid, liver and brain samples were obtained for up to 8 weeks after surgery.
Specimens were analyzed for changes in cytokine and thyroid hormone levels, as well as liver mitochondrial
alterations. Hepatic mitochondria isolated from animals bearing extended nigrostriatal lesion displayed in-
creased ROS production, while membrane potential (ΔΨ) and ATP production were signiﬁcantly decreased.
Reduced ATP production correlated with nigral neuronal loss. Thyroid hormone levels were signiﬁcantly in-
creased in serum of PD rats compared to sham animals while steady expression of selected cytokines was
detected in all groups. Hepatic enzyme functions were comparable in all animals. Our study indicates for
the ﬁrst time that in a rodent model of PD, hepatic mitochondria dysfunctions arise as a consequence of
nigrostriatal degeneration, and that thyroid hormone represents a key interface in this CNS-liver interaction.
Liver plays a fundamental detoxifying function and a better understanding of PD-related hepatic mitochon-
drial alterations, which might further promote neurodegeneration, may represent an important step for
the development of novel therapeutic strategies.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
Parkinson's disease (PD) is one of the most common and devastat-
ing neurological disorders in the elderly, and is principallyhydroxydopamine; CSF, cere-
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l rights reserved.characterized by the degeneration of dopaminergic neurons of the
substantia nigra pars compacta (SNc) projecting to the striatum. Al-
though PD is the prototypical movement disorder, numerous non-
motor functions are also affected in PD patients or PD animal models
[1,2]. The splanchnic district, in particular, is signiﬁcantly involved;
gastrointestinal dysfunctions [3–5] represent one of the most com-
mon PD non-motor symptoms. In this frame, a potential involvement
of the liver in the cascade of events triggered by the central dopami-
nergic deﬁcit has been occasionally proposed [6], but the issue has
never been fully investigated.
The liver is responsible for the body's mainstay protein metabo-
lism, synthesis and degradation, and possesses fundamental detoxify-
ing functions. It is highly connected with the CNS and evidence
indicates that the autonomic system plays an important role in regu-
lating hepatic functions [7]. Alterations of liver detoxiﬁcation capacity
and mitochondrial oxidative phosphorylation have been observed in
PD [8]. Moreover, detoxiﬁcation of medications and toxins is less efﬁ-
cient in PD patients compared to healthy individuals, thus possibly
reﬂecting altered liver function [9]. Impaired capacity of hepatic
P450 subsystems have been observed in late but not early onset PD
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in the etiology of the disease but may emerge as a consequence of
central neurodegenerative processes. Recent data indicate that brain
dopaminergic systems represent an important center regulating he-
patic cytochrome P450 activity [6,12,13]. Complex interactions may,
therefore, link liver function to the efﬁciency of the nigrostriatal
system, which represents the main source of dopamine in the CNS.
The development of animal models of PD has considerably im-
proved our understanding of the cellular and biochemical mecha-
nisms involved in the onset and progression of the disease. In
particular, loss of nigrostriatal dopaminergic neurons can be induced
by the intracerebral administration of the neurotoxin 6-OHDA in rats.
Six-OHDA is a hydroxylated analog of dopamine and its neurotoxicity
largely depends on its incorporation in dopaminergic neurons via se-
lectively and actively uptake by the dopamine transporter (DAT)
[14,15]. In this model unilateral injection of 6-OHDA in the rat stria-
tum results in extensive loss of striatal dopaminergic terminals and
a progressive retrograde degeneration of dopaminergic neurons in
the ipsilateral SNc [16]. The unilateral 6-OHDAmodel has been exten-
sively used to investigate various aspects of PD pathophysiology, as
well as to test innovative therapeutic strategies [16]. We have
recently shown that a massive reduction in fecal output, reminiscent
of the constipation seen in PD patients, is present in unilateral 6-
OHDA-lesioned animals [17], thereby supporting the use of the
“hemi-parkinsonian rat” as a model to assess PD-symptoms affecting
the splanchnic district. The central aim of this study was, therefore, to
evaluate whether and how changes in hepatic mitochondrial function
occur in the presence of on-going nigrostriatal degeneration caused
by intrastriatal injection of 6-OHDA.
2. Materials and methods
2.1. Animals, surgery, sacriﬁce and tissue processing
Male Sprague–Dawley rats (Charles River), weighing 200–225 g at
the beginning of the experiment, were housed two per cage, at
20–22 °C on a 12-h light–dark cycle, with food and water ad libitum.
Animals were left in the housing facilities for at least one week, before
the beginning of the experiments. All procedures were in accordance
with the European Communities Council Directive of 24 November
1986 (86/609/EEC) and were approved by the local Animal Care
Committee.
Rats (n=46) were anesthetized with sodium-thiopental (50 mg/
kg) and placed in a stereotaxic frame (Stoelting), with the incisor
bar positioned 3.3 mm below the interaural line. Animals received
an intrastriatal injection of 6-OHDA as described before [18] and
were sacriﬁced at different time points (24 h, 4 and 8 weeks) after
the neurotoxic insult. At the time of sacriﬁce animals were anesthe-
tized (50 mg/kg of sodium-thiopental) and 100–200 μL of cerebrospi-
nal ﬂuid (CSF) was withdrawn from the cisterna magna. Rats were
then decapitated, trunk bloodwas collected and serum aliquots stored
in liquid nitrogen. Brains were rapidly removed, and separated in two
portions containing the striatum or SNc using a cold Coronal BrainMa-
trix (2Biological Instruments). Striata from both hemispheres were
dissected out, weighted and stored, separately, at −80 °C, while
brain coronal portions containing the SNc were stored at −80 °C. At
the time of sacriﬁce, liver from each animal was also removed imme-
diately and processed for isolation of mitochondrial fraction.
2.1.1. Western blot
Striatal and liver samples were homogenized in lysis buffer (Cel-
Lytic, Sigma; 1:10, weight:volume) containing protease inhibitors
(Roche). Homogenates were centrifuged at 16,000 g for 10 min and
protein-containing supernatants aliquoted and stored at −80 °C for
successive assays. Protein content was quantiﬁed using the colori-
metric Bicinchoninic Acid Protein method (Sigma).Striatal and liver samples were separated on a poly-acrylamide gel
(4–12% NuPAGE Novex, Invitrogen) and transferred to a nitrocellu-
lose membrane (Invitrogen). Membranes were blocked using a com-
mercial buffer (Odyssey Blocking Buffer, LiCor BioSciences) and
incubated overnight at 4 °C with speciﬁc primary antibodies against:
tyrosine hydroxylase (TH) (Chemicon), β-actin (Santa Cruz) or dopa-
mine transporter (DAT). IRDye800 and IRD700 goat anti-rabbit or
anti-mouse secondary antibodies were used for detection (LiCor
Biosciences).
2.1.2. Striatal dopamine levels
Quantitative determination of dopamine (DA) was carried out on
striatal homogenates using a commercially available competitive
ELISA kit (IBL-Hamburg) according to the manufacturer's procedure.
All samples were analyzed in duplicates using a spectrophotometer
(ELx 808, Biotek) at 450 nm.
2.1.3. Immunohistochemistry
Serial coronal sections (25 μm) were cut throughout the SNc using
a cryostat (Leica) picked up on polylysine-coated slides (Thermo
Scientiﬁc) and stored at −80 °C. Immunohistochemical staining for
TH (Chemicon) was carried out as described before [18]. Image ana-
lyses were performed by a blinded investigator using an AxioSkop2
microscope (Zeiss) and a computerized image analysis system
(AxioCam MRc5, Zeiss) equipped with a dedicated software (AxioVi-
sion Rel 4.2, Zeiss). The number of TH-positive neurons was counted
bilaterally on every fourth section throughout the SNc. Neuronal sur-
vival was expressed as the percentage of TH-positive neurons on the
ipsilateral (lesioned) side with respect to the contralateral (intact)
side. This approach avoided possible bias due to inter-individual dif-
ferences. Loss of TH-positive neurons was determined as 100 minus
the percentage of surviving neurons.
2.2. Isolation of liver mitochondria
Whole livers (9 g) were washed with ice-cold saline and pro-
cessed immediately for mitochondria isolation by standard tech-
niques using differential centrifugation [19]. Brieﬂy, minced tissue
was homogenized in ice cold medium containing 0.25 M sucrose,
1 mM EDTA, 5 mM HEPES (pH 7.2; all from Sigma, Italy) using a
teﬂon/glass Potter homogenizer (Sartorius). The homogenate was
centrifuged at 1000 g for 10 min. The supernatant taken up and
centrifuged again 10 min at 10,000 g. The resulting pellet,
resuspended in medium containing 0.25 M sucrose, 5 mM HEPES
and centrifuged again 10 min at 10,000 g, was kept on ice and used
immediately for subsequent determination (see below). Single
mitochondrial preparations were obtained for each individual animal
(n=4–6) and protein concentration was determined using the Lowry
method [20].
2.2.1. Determination of hepatic mitochondrial ATP production
ATP production was measured using the Perkin Elmer ATPLite kit
according to the manufacturer's instructions. Bioenergetics experi-
ments were performed in state 3 in the presence of ADP. Brieﬂy,
hepatic mitochondria pellets, obtained from single animals, were
re-suspended in phosphate buffer (250 mM sucrose, 5 mM KH2PO4,
1 μM rotenone, pH 7.2) and 25 μM ADP and 6 mM succinate were
added. After twominutes suspensions were lysed and ATP production
measured [21]. Results represent mean±S.E of ATP (nmol) produced
per mg of protein. Luminescence changes were monitored using a
Perkin Elmer Victor 2 luminometer.
2.2.2. Determination of hepatic mitochondrial membrane potential
Mitochondrial membrane potential (ΔΨ) was assessed by mea-
suring the uptake of the ﬂuorescent dye rhodamine 123 [22]. Mea-
sures were taken from single hepatic mitochondrial preparations
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phate buffer (250 mM sucrose, 5 mM KH2PO4, 1 μM rotenone, pH
7.2 at 25 °C) containing 6 mM succinate, and 0.3 μM rhodamine 123.
The ﬂuorescence of rhodamine 123 was monitored using a Perkin
Elmer LS 50B ﬂuorescence spectrometer. Excitation and emission
wavelengths were 503 and 527 nm, respectively. ΔΨ was calculated
according to the following relationship: ΔΨ=−59 log (rhodamine
123) in/(rhodamine 123) out, assuming that the distribution of rho-
damine 123 between mitochondria and medium follows the Nernst
equation.2.2.3. Determination of hepatic mitochondrial reactive oxygen species
Generation of reactive oxygen species (ROS) by single hepatic mi-
tochondria preparation, obtained from individual animals, was fol-
lowed by the conversion of 2′,7′-dichloroﬂuorescein diacetate
(H2DCFDA) to ﬂuorescent 2′,7′-dichloroﬂuorescein (DCF). Freshly
isolated rat mitochondria were resuspended in 2 mL of phosphate
buffer (250 mM sucrose, 5 mM KH2PO4, 1 μM rotenone, pH 7.2 at
25 °C) and incubated for 10 min at 37 °C with 6 mM succinate and
5 mM H2DCFDA (Molecular Probes Inc.). Production of the ﬂuores-
cent derivative DCF as a function of time (minutes) was measured
using a microplate reader (Perkin Elmer Life Science, Monza, Italy).2.3. Treatment of isolated hepatocytes with 6-OHDA
Isolated rat hepatocytes were prepared by liver perfusion with
collagenase (Roche) as previously described [23]. Cell viability, esti-
mated at the beginning of the experiments, ranged between 85 and
90%. Cells were suspended (106 cells/mL) in Krebs–Henseleit-HEPES
buffer (118 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 1.3 mM CaCl2,
25 mM NaHCO3, 20 mM HEPES, pH 7.4) and incubated at 37 °C in
50-mL glass bottles under continuous ﬂuxing with 95% O2 and 5%
CO2. Increasing concentrations of 6-OHDA (12.5, 25, 50, 100 and
200 μM) were added to isolated hepatocytes and cell viability was
monitored at various time points (30, 60, 90 and 120 min) after addi-
tion of the toxin by measuring the activity of lactate dehydrogenase
(LDH) released into the medium as described before [24]. Maximal
LDH release was determined after exposing the cells to 10% of
triton-X-100 (50 μL into 1 mL of cell suspension). Hepatocyte ATP
content was determined 120 min after 6-OHDA-treatment using an
ATP Bioluminescence Assay Kit (Perkin Elmer, Italy), following the
manufacturer's instructions.2.4. Serum levels of hepatic enzymes and triiodothyronine (T3)
Evaluation of liver transaminases – alanine aminotransferase
(ALT), aspartate aminotransferase (AST) – and alkaline phosphatase
(AP) was performed on rat serum using an automated Hitachi 747 an-
alyzer (Roche/Hitachi).
Total T3 levels in serum were measured by using a time-resolved
ﬂuoroimmunoassay (AutoDELFIA, Wallac, Finland). Total serum T3
levels were measured by using a time-resolved ﬂuoroimmunoassay
(AutoDELFIA, Wallac, Finland).2.5. Serum and CSF levels of cytokines
Cytokines levels were determined using an infrared Multiplex
ELISA kit (Quansys Biosciences), according to the manufacturer's in-
structions, and data were quantiﬁed using an Odyssey Infrared Imag-
ing System (Li-Cor Biosciences). Minimal detection levels were: 2 pg/
mL for IL-1α, IL-6, IL-10 and IL-12p70; IL-1β: 50 pg/mL; IL-2: 4.5 pg/
mL; IL-4: 2.5 pg/mL; IFN-γ: 7.5 pg/mL and TNF-α 3 pg/mL).2.6. Plasma levels of 6-OHDA
Rats (n=8) received an intrastriatal injection of 6-OHDA or vehi-
cle, as described above (Surgery). Blood was drawn from the portal
vein 10, 30 min, 60 min and 24 h after toxin injection and plasma
from each animal was aliquoted and stored at −80 °C. Evaluation of
6-OHDA plasma level was determined by High Liquid pressure Chro-
matography (HPLC) on a reverse-phase ion-pairing system (Younglin
Instrument) using a C18 analytical column. The mobile phase compo-
sition was 50 mM citric Acid, 100 mM sodium phosphate, 100 mg/L
EDTA and 50 mg/L octylsulfate, pH 3.0, and ﬂow rate was 1 mL/min.
Electrodetection was performed at +0.35 V at a range of 0.5 nA.
Stock solution of 6-OHDA (1 mg/mL) was prepared freshly in
0.1 M perchloric acid and 0.1% ascorbic acid. For analysis 0.5 mL
aliquots of rat plasma, complemented with dinitroxybenzylamine
(3 ng/mL) as internal standard, were extracted using a catechol-
amines extraction kit (Chromsystems Diagnostics). Precision and
accuracy of the HPLC analysis were determined using a pool of rat
plasma spiked with different concentration of 6-OHDA (diluted
from stock solution) freshly prepared in perchloric acid 0.1 M and
0.1% ascorbic acid. Linearity was obtained for concentrations of up
to 1 mg/mL. The Limit of Detection and Limit of Quantiﬁcation were
determined as 2.27 and 1.59 ng/mL, respectively. The precision
intra-day and inter-day were of 3.7% and 6.0%, respectively.
2.7. Image analysis
Protein expression in the western blotting analysis was quantiﬁed
using an Odyssey Infrared Imaging System (Li-Cor Biosciences), all
samples being normalized to actin levels. Results represent the
percentage of protein expression in the injected striatumwith respect
to the intact, contralateral striatum.
Immunohistochemical image analysis was performed by an inves-
tigator, unaware of group distribution, using an AxioSkop II micro-
scope (Zeiss, Oberkochen, Germany) connected to a computerized
image analysis system (Zeiss). TH-positive cells in the SNc of both le-
sioned and intact hemispheres were counted in every ﬁfth section on
comparable sections for all the subgroups of treatment throughout
the entire nucleus. Results represent the percentage of the total
number of TH-positive neurons in lesioned (right) SNc vs intact side
(left) (neuron survival). In the absence of a stereological count, such
approach was chosen to avoid methodological biases due to inter-
individual differences and has been previously used to assess the
extent of 6-OHDA-induced lesion in the SNc.
2.8. Statistical analysis
All values are expressed as mean±S.E. Comparisons between
groups were carried out using the analysis of variance (ANOVA)
coupled with the Tukey's post-hoc or Bonferroni's correction using a
dedicated software (Prism 3 software, GraphPad Software). Correla-
tion among variables was assessed by the Pearson's correlation coef-
ﬁcient (r). Minimum level of statistical signiﬁcance was set at pb0.05.
3. Results
3.1. 6-OHDA-induced nigrostriatal degeneration
Intrastriatal injection of 6-OHDA induced loss of dopaminergic
terminals in the lesioned striatum compared with the intact side, as
detected by the reduced TH expression (Fig. 1A and B). This reduction
was minimal 24 h after injection of the neurotoxin, reached a signiﬁ-
cant (60–70%) level at 4 weeks and remained stable until 8 weeks
after surgery (Fig. 1A and B). Similarly, dopamine levels diminished
slightly after 24 h and were reduced by almost 80%, 4 and 8 weeks
after 6-OHDA injection.
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Fig. 1. Toxin-induced nigrostriatal degeneration. A. Representative western blot analy-
sis of TH expression in the left (contra-lateral, C) and injected (ipsi-lateral, I) striatum
observed 24 h, 4 and 8 weeks after unilateral injection of 6-OHDA or vehicle (sham).
M: molecular weight marker. Bands corresponding to TH (green) and actin (red) are
indicated. B. Results (n=4–6) indicate the percentage of TH and DA expression in
the right (R) vs left (L) striatum evaluated 24 h, 4 and 8 weeks after unilateral
6-OHDA injection or vehicle (sham). Black and white bars represent striatal TH expres-
sion and dopamine (DA) levels, respectively. C. Results (n=4–6) indicate the percent-
age of TH-positive neurons in the right (I) vs left (C) SNc detected 24 h, 4 and 8 weeks
after unilateral injection of 6-OHDA or vehicle (sham). * and # pb0.001 vs sham.
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positive neurons in the ipsilateral SNc (Fig. 1C). Cell loss was
observed at 4 weeks after surgery and remained stable until
8 weeks after the neurotoxin infusion. No cell loss was detectable
after 24 h.
3.2. Nigrostriatal degeneration and liver mitochondria dysfunction
Liver mitochondria obtained from animals sacriﬁced 4 or 8 weeks
after 6-OHDA injection exhibited a signiﬁcant decrease in ATP pro-
duction, compared with the respective vehicle-treated rats. Interest-
ingly, ATP reduction correlated with the extent of neuronal loss
(Fig. 2A and B). Similarly, the measurement of membrane potential
showed a statistically signiﬁcant decrease 8 weeks after infusion of
the toxin, with respect to mitochondria obtained from control ani-
mals (Fig. 2C). This decrease was associated with a higher production
of reactive oxygen species (ROS) of hepatic mitochondria obtainedfrom animals 8 weeks after 6-OHDA-treatment (Fig. 2D and E). No al-
terations were detected in hepatic mitochondria isolated 24-hours
after the toxic insult (Fig. 2A and C).
To exclude a direct effect of the toxin on liver, blood was obtained
from 6-OHDA and sham animals 10, 30, 60 min and 24 h after intras-
triatal injection of 6-OHDA. No 6-OHDA, at any time point considered,
was detected in plasma of animals following HPLC analysis (data not
shown).
DAT expression, required for cellular uptake and 6-OHDA-toxicity,
was not detected in liver extracts (Fig. 3A).
When suspensions of isolated hepatocytes were challenged with
increasing concentration – 12.5, 25, 50, 100 and 200 μM – of 6-
OHDA, no changes were observed either in LDH release, evaluated
as an index of cell viability (Fig. 3B), or ATP content (Fig. 3C), as mea-
sured for up to 120 min.
3.3. Effect of 6-OHDA-induced nigrostriatal degeneration on levels of
thyroid hormone, cytokine expression and liver enzyme activities
Thyroid hormones have been recognized as crucial modulators of
hepatic mitochondrial efﬁciency. Interestingly, serum levels of triio-
dothyronine (T3) were signiﬁcantly increased in PD animals 4 and
8 weeks after 6-OHDA injection when compared to sham animals
(Table 1).
The concentrations of cytokine levels that may potentially affect
hepatic mitochondrial function were measured in both serum and
CSF. Levels were generally low or not detectable in sham animals
and remained unchanged following 6-OHDA injection, at all time
points considered in this study (Table 2A and 2B).
Similarly, serum level of AST, ALT and AP – index of liver viability/
function – obtained from animals sacriﬁced 24 h, 4 weeks and
8 weeks after 6-OHDA injection were not modiﬁed with respect to
those obtained from sham animals (Fig. 3D).
4. Discussion
PD is considered primarily a movement disorder, but non-motor
dysfunctions are prominent and well-recognized features of the dis-
ease. Previous data have suggested that altered hepatic enzyme func-
tions may be associated with PD [8]. However, in view of the long pre-
clinical phase of the disorder, it is unclear whether such dysfunctions
may be a cause or a consequence of the loss of dopaminergic neurons,
which starts well before PD symptoms become overt. While defective
liver activity may cause forms of hepatic-derived encephalopathies
characterized by extrapyramidal symptoms [25,26] and neurological
symptoms [27] through activation of the liver–brain axis, to date no
studies have directly addressed the biochemical, pathological and
functional aspects of hepatic dysfunction consequent to lesion of cen-
tral dopaminergic pathways. Our data indicate, for the ﬁrst time, an
association between nigrostriatal degeneration and the subsequent
emergence of hepatic mitochondrial alterations.
4.1. Hepatic mitochondrial activity is reduced in rats with nigrostriatal
lesion
In this study, we used a well-characterized rodent PD model [16]
relying on the unilateral intrastriatal injection of 6-OHDA, which
prompts rapid damage to striatal dopaminergic terminals followed
by delayed, progressive, and retrograde loss of nigral cell bodies. Bi-
lateral injections of the neurotoxin are usually avoided because asso-
ciated with marked aphagia, adipsia and high mortality rate [28].
Bilateral lesioning would therefore require intense nursing care, in-
cluding administration of high-caloric liquid diet to maintain body
mass [29] that might bias any evaluation within peripheral systems.
Characteristic time-dependent nigrostriatal degeneration [30] was
observed with modest reduction of striatal dopamine and TH
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OHDA injection, while extended neurodegeneration was observed in
both nuclei after 4 weeks and remained stable for up to 8 weeks.
Analysis of hepatic mitochondria activity revealed no differences in
mitochondrial ΔΨ, as well as ATP and ROS production in lesioned
compared to control animals 24 h after toxin injection. Conversely,
hepatic mitochondria isolated from rats bearing an extended 6-
OHDA-induced lesion (4 and 8 weeks), displayed signiﬁcantly re-
duced energy production capacity and ΔΨ while their propensity to
generate ROS was signiﬁcantly increased, clearly indicating the pres-
ence of hepatic mitochondrial dysfunctions in PD animals. Important-
ly, reduction of mitochondrial ATP release in liver correlated with the
percentage of neuronal cell loss in the SNc.
We excluded the possibility that the toxin may have in some way
directly affected liver function, by leaking outside the CNS and enter-
ing the bloodstream based on a number of substantial evidence. Firstof all, 6-OHDA is very unstable and readily oxidizes at the injection
site [31]; it is therefore unlikely that, following intra-cerebral injec-
tion, the toxin might have leaked into the bloodstream and acted on
a peripheral organ. Accordingly, we demonstrate that no trace of
6-OHDA could be detected in plasma of lesioned-rats following intra-
cerebral injection, even at very early time points (10 or 30 min post-
injection). In addition, 6-OHDA-toxicity is mostly linked to the pres-
ence of DAT, that is required for intracellular transport of the toxin
[15], although at high toxin concentration, auto-oxidation may
cause unspeciﬁc death of any cell type. We show that hepatocytes
do not express any DAT and are fully resistant to 6-OHDA-treatment
in vitro, even at high toxin concentrations.
Our data unequivocally demonstrate that hepatic alterations are
not detected at the onset of the toxin-induced neurodegenerative
process but emerge as a consequence of extended and stable degen-
eration of nigrostriatal dopaminergic neurons.
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rats, were incubated with increasing concentration of 6-OHDA (0, 12.5, 25, 50, 100 and 200 μM) and % lactate dehydrogenase (LDH) release, as an index of cell viability, was eval-
uated after 30, 60, 90 and 120 min. C. Isolated hepatocytes were incubated with increasing concentration of 6-OHDA (0, 12.5, 25, 50, 100 and 200 μM) and ATP content was eval-
uated after 120 min. Each measurement represents the mean±S.E. of 4–6 separate hepatocyte preparations. D. Serum levels of hepatic enzymes. Values (mean±SD) are given in U/
mL and were measured 24 h, and 4 and 8 weeks after intrastriatal injection of 6-OHDA or vehicle (Sham). AST: alanine aminotransferase; AST: aspartate aminotransferase; AP: al-
kaline phosphatase.
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A crucial question arising from our results is how the selective
nigrostriatal denervation may affect mitochondrial function in the
liver. A potential explanation may lie in the neuroinﬂammatory re-
sponse associated with nigrostriatal damage [32,33]. A previous
study has demonstrated that unilateral intrastriatal injection of
6-OHDA and consequent DA depletion in mice compromise both the
humoral and the immune systems with repercussions in peripheral
organs, such as the spleen and mainly the liver [34]. The authors
show that in lesioned animals under stress conditions, such as abacterial infection, the liver is signiﬁcantly more vulnerable while
global morphology and functional integrity of the organ are pre-
served. Similarly, we show that signiﬁcant changes in hepatocyte mi-
tochondrial physiology are triggered by a central dopaminergic
lesion, while gross liver functions are not affected.
Cytokines are key mediators in CNS-immune system crosstalk and
are abundantly synthesized by activated glial cells and/or damaged
neurons. Altered cytokine expression is well documented in brains
of PD patients, as well as parkinsonian rats [33,35–37] and could in-
tervene on and modulate cell-mediated and humoral components of
peripheral immune response and tissues/organs [29,34,38,39]. Intra-
Table 2B
Cytokine levels in CSF.
Sham 6-OHDA
4 weeks 8 weeks
IL-1 α 4.75±0.14 5.1±0.3 4.7±0.1
IL-1 β 137.9±3.3 156.4±17.1 131.7±3.6
IL-2 7.0±0.9 7.4±1.8 6.1±0.3
IL-4 12.2±0.2 12.4±0.1 12.3±0.2
IL-6 85.1±9.5 77.7±1.5 77.1±2.4
IL-10 2.5±0.1 3.0±0.2 2.6±0.1
IL-12p70 28.5±1.7 28.7±1.0 26.4±0.8
IFN-γ 8.6±0.4 9.3±0.3 8.2±0.4
TNF-α 3.9±0.1 4.1±0.1 3.7±0.1
Values (mean±SE) are expressed in pg/mL. Limit of detection was: IL-1α: 2 pg/mL; IL-
1β: 50 pg/mL; IL-2: 4.5 pg/mL; IL-4: 2.5 pg/mL; IL-6: 2 pg/mL; IL-10: 2 pg/mL; IL-
12p70: 2 pg/mL; IFN-γ: 7.5 pg/mL and TNF-α: 3 pg/mL; n.d.: not determined, indicates
that values were bellow detection level; CSF = cerebrospinal ﬂuid. CSFs at 24 h were
not available.
Table 1
T3 level in serum.
Sham 6-OHDA
4 weeks 8 weeks
T3 3.21±0.4 4.45±0.3* 4.55±0.8*
T3; * pb0.05 vs sham. Values represent the mean±SD. Sham values were equal 4 and
8 weeks after 6-OHDA injection and are pooled under a single column. T3 levels at 24 h
were not available.
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example, cause massive inﬂammatory reaction in brain tissues and
affect hepatic levels of P450 isozymes [40]. Conversely, we did not de-
tect any signiﬁcant changes in cytokines levels, in either plasma or
CSF, of lesioned compared to control animals. Cytokine release is a
rapid and short-lived phenomenon; we cannot exclude that acute,
transient changes that occurred as an early event, possibly triggered
a signaling cascade, leading to delayed hepatic mitochondrial alter-
ations in lesioned animals. A more extensive time course analysis,
taking into consideration earlier time points, would be, therefore,
required.
Alteration of central cytokine levels could also intervene on auto-
nomic and endocrine systems [41] that bi-directionally connect liver
to CNS and play an important role in hepatic function and regulation
[7]. The hypothalamus, that sends parasympathetic and sympathetic
signals via the celiac ganglia and especially the vagal nerve, has
been shown to regulate hepatic function through a neuro-endocrine
connection based on secreted soluble factors. Hepatic mitochondria
dysfunction may therefore indirectly arise from altered sympathetic
nerve [42,43] and/or hypothalamic–pituitary–adrenal (HPA) activity
consequent to a central increased cytokine expression [33] that ac-
companies neurodegeneration. Sustaining this hypothesis, both sym-
pathetic nerves and HPA are knowingly affected in PD patients [44]
and 6-OHDA-lesioned animals [34,45–48].4.3. Central dopaminergic denervation and hepatic mitochondrial
function
The importance of dopaminergic systems in liver regulation has
been previously suggested [6,12,13] and while precise mechanisms
remain elusive a crucial role of increased T3 levels has been sug-
gested. It has been shown that central treatment with dopaminergic
drugs can modulate peripheral levels of T3 by affecting the tuberoin-
fundibular and mesolimbic pathways [13]. Our study shows a signiﬁ-
cant increase of serum T3 levels in PD animals, 4 and 8 weeks after
6-OHDA injection, and further sustains an important role for this hor-
mone in the delayed emergence of hepatic mitochondrial dysfunction
detected in rats bearing a PD-like lesion of nigrostriatal tract. Thyroid
hormones have been recognized as crucial modulators ofTable 2A
Cytokine levels in serum.
Sham 6-OHDA
24 h 4 weeks 8 weeks
IL-1 α n.d. n.d. n.d. n.d.
IL-1 β 73.8±2.5 76.8±4.1 85.5 ±4.1 78.3±5.5
IL-2 n.d. n.d. n.d. n.d.
IL-4 6.2±1.8 8.4±2.4 9.0±1.3 9.5±0.6
IL-6 n.d. n.d. n.d. n.d.
IL-10 n.d. n.d. n.d. n.d.
IL-12p70 7.4±1.8 7.9±2.6 11.7±2.4 9.8±3.8
IFN-γ n.d. n.d. n.d. n.d.
TNF-α n.d. n.d. n.d. n.d.mitochondrial efﬁciency [49] and high afﬁnity receptors for thyroid
hormone have been detected in liver mitochondria [50]. In vivo stud-
ies showed that T3-treatment causes decreased hepatic mitochondri-
al ΔΨ. We have also previously demonstrated that in rats with
increased T3 levels, similar to those observed in the present study, a
signiﬁcant reduction of hepatic ATP levels could be detected com-
pared with levels in euthyroid rats [51]. In addition, livers from hy-
perthyroid rats, showed a GSH/GSSG ratio signiﬁcantly lower than
euthyroid rats, suggesting higher hepatic susceptibility to free radical
formation. The expression of several nuclear genes encoding mito-
chondrial proteins is T3-regulated, as shown for beta-F1ATPase and
several sub-units of the respiratory chain [52]. Recently, proteomic
characterization has indicated that elevated peripheral T3 levels can
cause the differential expression of liver proteins involved in energy
metabolism and response to oxidative stress, as well as alteration of
hepatic mitochondrial protein [53].
Clinical studies assessing thyroid function in PD patients also
showed signiﬁcant abnormalities in the thyroid laboratory tests and
a “subclinical” hyperthyroidism was found to be prevalent in the PD
patients when compared to age-matched controls [54]. Altered thy-
roid hormone levels could derive from HPA dysfunctions, knowingly
present in PD patients [44] and 6-OHDA-lesioned animals
[34,45–48], that may in turn cause disturbance in pituitary hormones
[55]. Here, we demonstrated that extended nigrostriatal degeneration
was paralleled by a signiﬁcant increase in serum T3, that, in line with
previously published data, can in turn induce alterations of hepatic
mitochondria function, in particular decreased mitochondrial ΔΨ
and increased ATP production. These results therefore indicate the
existence of a close interconnections between neurodegeneration, al-
tered levels of hormones and soluble factors and hepatic mitochon-
drial dysfunction.4.4. Hepatic mitochondria dysfunction and neurodegeneration
The metabolically active liver requires continuous ATP synthesis,
thus hepatocytes contain a relatively high density of mitochondria
compared to other cell types. Hepatic manifestations of mitochon-
drial disorders range from steatosis, cholestasis and chronic liver
disease [56]. Mitochondrial dysfunction is the commitment step in
hepatocytes cell death, and hepatocytes cell death is dependent on
mitochondria. Notably, mitochondrial impairments and permeabili-
zation can affect cell viability and cause cell death leading hepato-
cytes down the apoptotic or necrotic pathway [57]. Mitochondrial
dysfunctions also represent the major determinant of hepatotoxicity
and could be the major mechanism of drug-induced liver disease
[58].
Fig. 4. The liver–brain axis. There are signiﬁcant connections between the brain and pe-
ripheral organs, especially the liver. These connections are based i) on nervous signal-
ing, through the parasympathetic (blue arrow) and sympathetic innervation (orange
arrow) and ii) on molecular signaling (black arrows). The nervous pathway relies on
the activation of the vagal and dorsal pathways emerging from the DMV in the brain-
stem. Another essential nervous pathway is the HPA that originates from the Hypothal-
amus. Molecular signaling systems include a broad spectrum of soluble factors,
neurotransmitters and cytokines that are released in the blood stream and reach the
target sites. In pathological conditions, like those present in PD, molecules and ROS,
synthesized in brain lesioned-regions and released in CSF and in systemic circulation,
might modify macromolecules, especially those present in the CSF, which might
exert a detrimental effect on peripheral organs and induce hepatic mitochondria dys-
functions. Reduced hepatic capacity of detoxifying neurotoxins and contaminants
may promote the release of ROS and toxic metabolites that may, in turn, cross the
brain blood barrier and affect the brain. The establishment of such a vicious cycle
might sustain and/or exacerbate the pathology, independently of the initial source of
damage.
183M. Vairetti et al. / Biochimica et Biophysica Acta 1822 (2012) 176–184Our data indicate that severe hepatic injury was not present in
parkinsonian animals, as evidenced by normal serum hepatic enzyme
values. This is not entirely surprising when considering, for example,
that despite the ultra-structural changes observed in the hepatic mi-
tochondria of some patients with Amyotrophic Lateral Sclerosis (i.e.
mitochondrial para-crystalline inclusions), in those same patients
no overt liver dysfunction was actually reported [59]. Interestingly,
while ranges liver function (ASL, AST and PA) are normal in PD pa-
tients, decreased albumin level, a marker of hepatic synthetic ability
has been observed [60], suggesting some altered hepatic functions.
In hepatic mitochondria of 6-OHDA-lesioned rats we detected asigniﬁcant depolarization of the mitochondrial ΔΨ, an assay com-
monly used to assess mitochondria integrity. Dissipation of mito-
chondrial ΔΨ causes uncoupling of electron transport through the
respiratory chain and phosphorylation reaction for ATP synthesis
[61]. Intact ΔΨ is required not only to drive ATP synthesis but also
to support other mitochondrial functions such as Calcium homeosta-
sis, protein trans-membrane transport and cellular redox balance
[62]. Mitochondria are also the major intracellular source of ROS,
which generation is exponentially dependent on mitochondrial ΔΨ
[63]. Therefore, subtle hepatic mitochondrial alterations, initially
caused by a distant neuronal damage may reciprocally sustain ongo-
ing neurodegenerative process (Fig. 4).
5. Conclusion
The groundwork evidence that interestingly emerges for the ﬁrst
time from our work is that the liver can be, directly or indirectly, af-
fected by a primary central dopaminergic defect. Although the precise
mechanisms still need to be clariﬁed, this phenomenon likely occurs
through the activation of signaling pathways and/or release of soluble
mediators, including hormones, generated in response to the neuro-
degenerative process.
A very recent report [64] indicates that, after stroke, altered nor-
adrenergic innervation in the liver can signal specialized hepatic im-
mune cells (iNKT cells) to promote systemic immunosupression
suggesting that such signaling pathways involving neurotransmitters
might also be involved in neurodegenerative diseases. This study sus-
tains our data and further demonstrates that the CNS communicates
with peripheral systems and organs, through signaling pathways in-
volving neurotransmitters, to regulate immune and inﬂammatory re-
sponse and even regulate the central nervous system itself through
feedback mechanisms. Different studies have demonstrated how vice-
versa dysfunctions at the hepatic level may have secondary effects on
brain integrity [65]. Combination of factors that, per se, seem weakly
toxic or even ineffective might enable the self-perpetuation of an ini-
tially subtle toxic insult. Liver endows a fundamental position and
role in the elimination of both endogenous and exogenous toxic
molecules, preventing their accumulation and entry into the CNS. In
this context, it might represent an important player in a vicious circle
in which loss of dopaminergic neurons, directly or indirectly, induces
hepatic dysfunctions, which in turn further promote and sustain the
ongoing neurodegenerative process. Taken together these data indi-
cate how, independently of the primum movens factor between the
two, a vicious cycle can be established and the brain–liver axis be-
comes a “two-ways around” source of reciprocal damage.
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